Literature DB >> 33314018

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.

Albrecht Betrains1,2, Laurent Godinas3, F J Sherida H Woei-A-Jin4,5, Wouter Rosseels1, Yannick Van Herck4, Natalie Lorent3, Daan Dierickx6,7, Veerle Compernolle8,9, Geert Meyfroidt10,11, Lore Vanderbeke1,12, Valentijn Vergote13, Katrien Lagrou14, Peter Verhamme15,16, Joost Wauters1,2, Pieter Vermeersch14, Timothy Devos6,17, Piet Maes13, Steven Vanderschueren1,2.   

Abstract

Entities:  

Keywords:  B-cell depletion; anti-CD20; neutralising antibodies; protracted COVID-19; rituximab

Mesh：

Substances：

Year:  2020        PMID： 33314018     DOI： 10.1111/bjh.17266

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  17 in total

Review 1.  Use of convalescent plasma in COVID-19 patients with immunosuppression.

Authors:  Jonathon W Senefeld; Stephen A Klassen; Shane K Ford; Katherine A Senese; Chad C Wiggins; Bruce C Bostrom; Michael A Thompson; Sarah E Baker; Wayne T Nicholson; Patrick W Johnson; Rickey E Carter; Jeffrey P Henderson; William R Hartman; Liise-Anne Pirofski; R Scott Wright; De Lisa Fairweather; Katelyn A Bruno; Nigel S Paneth; Arturo Casadevall; Michael J Joyner
Journal:  Transfusion       Date:  2021-06-01       Impact factor: 3.337

Review 2.  The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.

Authors:  Stephen A Klassen; Jonathon W Senefeld; Patrick W Johnson; Rickey E Carter; Chad C Wiggins; Shmuel Shoham; Brenda J Grossman; Jeffrey P Henderson; James Musser; Eric Salazar; William R Hartman; Nicole M Bouvier; Sean T H Liu; Liise-Anne Pirofski; Sarah E Baker; Noud van Helmond; R Scott Wright; DeLisa Fairweather; Katelyn A Bruno; Zhen Wang; Nigel S Paneth; Arturo Casadevall; Michael J Joyner
Journal:  Mayo Clin Proc       Date:  2021-02-17       Impact factor: 7.616

3.  Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.

Authors:  Rémy Duléry; Sylvain Lamure; Marc Delord; Roberta Di Blasi; Adrien Chauchet; Thomas Hueso; Cédric Rossi; Bernard Drenou; Bénédicte Deau Fischer; Carole Soussain; Pierre Feugier; Nicolas Noël; Sylvain Choquet; Serge Bologna; Bertrand Joly; Laure Philippe; Milena Kohn; Sandra Malak; Guillemette Fouquet; Etienne Daguindau; Yassine Taoufik; Karine Lacombe; Guillaume Cartron; Catherine Thiéblemont; Caroline Besson
Journal:  Am J Hematol       Date:  2021-05-12       Impact factor: 13.265

4.  Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.

Authors:  Teruhito Takakuwa; Yu Nakagama; Mayo Yasugi; Toshiki Maeda; Kenji Matsuo; Ayako Kiritoshi; Ryo Deguchi; Naohiro Hagawa; Wataru Shibata; Kazuhiro Oshima; Katsumi Yamamoto; Kenichiro Uchida; Tomohiro Noda; Koichi Yamada; Tetsuro Nishimura; Hiromasa Yamamoto; Yasutoshi Kido; Masayuki Hino; Hiroshi Kakeya; Yasumitsu Mizobata
Journal:  Intern Med       Date:  2021-12-01       Impact factor: 1.271

5.  Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.

Authors:  Timothy Devos; Quentin Van Thillo; Veerle Compernolle; Tomé Najdovski; Marta Romano; Nicolas Dauby; Laurent Jadot; Mathias Leys; Evelyne Maillart; Sarah Loof; Lucie Seyler; Martial Moonen; Michel Moutschen; Niels Van Regenmortel; Kevin K Ariën; Cyril Barbezange; Albrecht Betrains; Mutien Garigliany; Matthias M Engelen; Iwein Gyselinck; Piet Maes; Alexander Schauwvlieghe; Laurens Liesenborghs; Ann Belmans; Peter Verhamme; Geert Meyfroidt
Journal:  Eur Respir J       Date:  2022-02-10       Impact factor: 16.671

6.  Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden.

Authors:  Karin Holm; Maria N Lundgren; Mona Landin-Olsson; Magnus Rasmussen; Jens Kjeldsen-Kragh; Oskar Ljungquist; Blenda Böttiger; Christian Wikén; Jonas Öberg; Nils Fernström; Ebba Rosendal; Anna K Överby; Julia Wigren Byström; Mattias Forsell
Journal:  BMC Res Notes       Date:  2021-12-04

Review 7.  Impact of COVID-19 in patients with lymphoid malignancies.

Authors:  John Charles Riches
Journal:  World J Virol       Date:  2021-05-25

Review 8.  COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.

Authors:  Jason D Goldman; Philip C Robinson; Thomas S Uldrick; Per Ljungman
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

9.  Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.

Authors:  Honorine Fenaux; Romain Gueneau; Amal Chaghouri; Benoît Henry; Lina Mouna; Anne-Marie Roque-Afonso; Christelle Vauloup-Fellous
Journal:  BMC Infect Dis       Date:  2021-12-07       Impact factor: 3.090

10.  Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.

Authors:  Andreas E Kremer; Anita N Kremer; Carsten Willam; Simon Völkl; Johan Verhagen; Susanne Achenbach; Edith D van der Meijden; Vanessa Lang; Michael Aigner; Clara Maier; Matthias Tenbusch; Klaus Korn; Gloria Lutzny-Geier; Silvia Spoerl; Richard Strauß; Marcel Vetter; Klaus Überla; Markus F Neurath; Andreas Mackensen; Mario Schiffer; Holger Hackstein
Journal:  Eur J Immunol       Date:  2021-09-03       Impact factor: 6.688
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.